Ingliptin | Mechanism of Action

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Action

Pharmacology: Pharmacodynamics: Mechanism of action: Sitagliptin inhibits dipeptidyl peptidase IV (DPP-IV) enzyme resulting in prolonged active incretin levels. Incretin hormones (eg. glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and decreasing glucagon secretion results in decreased hepatic glucose production. Under normal physiologic circumstances, incretin hormones are released by the intestine throughout the day and levels are increased in response to a meal; incretin hormones are rapidly inactivated by the DPP-IV enzyme.
Pharmacokinetics: Absorption: Rapid.
Distribution: ~198 L.
Protein-binding: 38%.
Metabolism: CYP3A4 and 2C8.
Bioavailability: ~87%.
Half-life elimination: 12.4 hours.
Time to peak: 1-4 hours.
Excretion: Urine 87% (~79% as unchanged drug, 16% as metabolites); feces 13%.

Ingliptin Mechanism of Action

sitagliptin

Manufacturer:

Community Pharm PCL

Distributor:

Community Pharm PCL

Marketer:

Community Pharm PCL